text:
South Korea is cutting-edge in so many ways, except its foreign policy.
Regions / Asia & Pacific
Forty years later, unexploded bombs from America's secret war in Laos continue to kill dozens each year.
This article examines the protests held in Japan on June 29, 2012 in response to the government's call for resumption of nuclear energy after Fukishima.
Walden Bello journeys through Burma's changing political landscape.
North Koreans now know more about the outside world than ever before. So, why haven't they changed their regime?
This article addresses the conflicts of interest between nuclear scientists and the need for disarmament.
And what is the relationship of transnational organized crime to state power?
Can a new book help shake the world's indifference to North Korea's prison camps?
The Indo-U.S. friendship is on the line.
When it comes to Vietnam and China, the frenemy of our frenemy is an even closer frenemy.


text:
Video Projects
Independent Film
Television and Commercial
Theatre Portfolio
Childrens Theatre
Event Costumes
Print Work Projects
Subscribe to this RSS feed
Men And Women Perhaps Have Their Particular Favorites, But Everybody Loves A Great
Fireworks are lots of things to a lot of people. To many, they are strictly enchanting, mainly the kinds that will cascade thru the nighttime heavens using trailers of different pigmented sparkles little by little plummeting like embers on the earth. These are the versions which will make folks say, "Ooh" and later "Ahh" and really feel nearly as if they actually may possibly reach right up and really touch the gorgeous colorings plummeting downward.
And then there are individuals that like their particular fireworks to generally be high in volume and also energetic, much like a good
outside affair. They're that particular type that enjoys things that go "Boom!" in general, no matter whether they happen to be items that clash or hectic TV programs whereby adrenaline runs at the maximum and then the bad man practically is the victor. These folks enjoy seeing a number of vibrant lights as well, but would surely be dissatisfied whenever they traveled to buy fireworks, and not one were actually available besides silent types.
Also, that brings up a superb point concerning finding the best destination to purchase fireworks.
where to buy fireworks
are apt to become your best choice, and shops similar to this do not have to maintain a local store, and they are in a position to take their funds in the purchase of the most beneficial fireworks obtainable, the highest traveling, brightest tinted, as well as, the very noisiest.
At the same time valued, of course, are definitely the sparklers for kids and too, the new as well as specific effects which come about from time to time - for who won't desire to truly feel they were seeing the best brand new fireworks offered? We all want that, because if perhaps the simple truth was recognized, most people enjoy a great fireworks display!

subset: commoncrawl


text:
Take a tour
Success Stories
invite your friends
success stories
- Select Menu -
Invite your friends
Success Stories
OT: Inability to Get Over It
I am still angry about something that happened several years ago. At the time, it ruined a (what I thought to be) amazing relationship. But it also set the stage for a rekindled, and obviously better, relationship that I am currently in.
The problem is that the person that caused the big commotion is the person that I'm really angry with, and I cannot let it go. She lives far away, so it's not like I deal with her that much. But with nonsense like MySpace out there, it makes it really hard to ignore her existence even from hundreds of miles away.
I don't know what's wrong with me. I don't want to hold a grudge, but she's such an awful person that I can't help it. And I will have to deal with her in the future (once or twice a year, I visit my best friend, who for some reason still associates with her). When I see her (which has only happened a few times since the incident), it's so hard for me not to punch her in her smug little face. I don't know how to let this go.
Has anyone else had a problem with ridiculous grudges against people that shouldn't matter? And if so, have you gotten over it? How?
Thu. Nov 29, 8:28am
I think we all at sometime in our lives go through this. This person hurt you emotionally and that is what is hard to accept. There are going to be rude, hurtful and mean people in this world. I think maybe what is keeping it kindled is you haven't let go of those feelings by either writing it all down excactly what you would say to her or you just haven't confronted her about the incident. I personally would write it all down then I would actually take the time the next time I was in the area and actually invite her for coffee and just tell her (don't put her on the defensive because this will only create more of a problem) place it with "I" words, such as: "I wanted us meet today because I need to put some closure to xyz" then let her know "I felt betrayed, angry at you when xyz happened. You just have to be prepared that she may not even remember what she did in the first place but, confronting it is the first step for you to heal the hurt.
Thursday, November 29, 2007, 9:14 AM
Sounds like you're putting a disproportionate amount of blame for your break-up on the girl than on the boy. Rethink that.
Thursday, November 29, 2007, 9:52 AM
I discovered that living well and being secure in myself really makes those encounters much more pleasant. Remember you reap what you sow and if she's that nasty and unpleasant i don't doubt she's sowed quite a bit. Just remain calm and serene in the knowledge that you too are reaping what you sowed - a great relationship and a good life. Living well is truly the best revenge so far as I'm concerned. Anything you could do to her would only lessen the impact of that and make you look as small as her so I'd let things be and just rise above it.
As far as letting things go - when I realize that in spite of any negatively, I love where I am and wouldn't have my life any other way, I realize I have let go. Poison in your heart only poisons you - it hurts no one else, so by letting go of the poison you heal yourself. It doesn't change or excuse what the other person did but it gives you the ability to deal with them on your terms. I'm not saying you have to be buds with them after letting go, but while you still harbor all those bad feelings she has the power to get a reaction out of you and make you feel bad. Get rid of that and you will feel a ton better and remove any power her actions have over your emotions. Best wishes!
Thursday, November 29, 2007, 10:10 AM
buck up, move on and know that you're wasting your time thinking about it, which means she's still getting the best of you. You deserve better than that. We all have things that piss us off or disappoint us. It's how you deal with it that shows your true colors. What color do you want to be?
Thursday, November 29, 2007, 10:44 AM
Think of it this way...she doesn't DESERVE the amount of energy you spend thinking about her!! And feel grateful that she accelerated your finding this new, fabulous relationship!
Thursday, November 29, 2007, 11:17 AM
I'm just like you. I see people because they are still in my social groups and I can't stand it. If you get some clarity and resolution, please don't forget to post it here. I'm still trying to learn how to do this.
Thursday, November 29, 2007, 11:29 AM
Related Content:
How To Lose Weight- The Basics
Weight Watchers Points System
The Fat Smash Diet
The Eat To Live Diet
The Beck Diet Solution
How To Get The Motivation To Lose Weight
How To Be Successful Using PEERtrainer
How To Burn Fat
Online Weight Loss Support- How It Works
Does Green Tea Help You Lose Weight?
Tips On Using PEERtrainer
Visit The PEERtrainer Community
Diet and Fitness Resources
Weight Watchers Meetings
Learning To Inspire Others: You Already Are
Writing Down Your Daily Workouts
Spending Money On A Personal Trainer?
How I Became A Marathon Runner
Preventive Health
How To Prevent Injuries During Your Workout
Flu Season: Should You Take The Flu Shot?
Are You Really Ready To Start PEERtrainer?
Super Foods That Can Boost Your Energy
Reversing Disease Through Nutrition
New Diet and Fitness Articles:
Weight Watchers Points Plus
How To Adjust Your Body To Exercise
New: Weight Watchers Momentum Program
New: PEERtrainer Blog Archive
Review Of The New Weight Watchers Momentum Program
Weight Loss Motivation by Joshua Wayne:
Why Simple Goal Setting Is Not Enough
How To Delay Short Term Gratification
How To Stay Motivated
How To Exercise With A Busy Schedule
Real World Nutrition and Fitness Questions
Can Weight Lifting Help You Lose Weight?
Are Protein Drinks Safe?
Nutrition As Medicine?
Everyday Weight Loss Tips
How To Eat Healthy At A Party
How To Eat Out And Still Lose Weight
The Three Bite Rule
Tips On How To Stop A Binge
Introducing The PEERtrainer Cheat System
How To Speed Up Weight Loss
How To Get Motivation To Lose Weight
Weight Watchers: The New Science!
3 Myths About Weight Loss With JJ Virgin
Related Article :
New PEERtrainer Articles :
Why Green Tea Helps You Lose Weight
How To Lose A Lot Of Weight, Fast
5 Things You Must Know Before Doing A Cleanse
New: How To Build Muscle
What Is The Best Kind Of Protein Powder?
The Master Cleanse
Will Removing Gluten From Your Diet Help You Lose Weight?
How To Obliterate Your Limitations
How To Get The Motivation To Exercise
How To Stop Feeling Tired
Dr. Joel Fuhrman's Super Immunity Diet
The PEERtrainer Diet
Is Portion Control Keeping You Fat?
The Ultimate Guide To Dietary Fiber
P90X? Do Burst Training Instead
Weight Watchers Points Changes For 2012
Can Diet Soda Cause You To GAIN Weight?


text:
Myopia, or nearsightedness, is the most common human eye disorder in the world, and is a significant global public health concern. Along with cataract, macular degeneration, infectious disease, and vitamin A deficiency, myopia is one of the most important causes of visual impairment worldwide. Severe or high-grade myopia is a leading cause of blindness because of its associated ocular morbidities of retinal detachment, macular choroidal degeneration, premature cataract, and glaucoma. Ample evidence documents the heritability of the non-syndromic forms of this condition, especially for high-grade myopia, commonly referred to as myopic spherical refractive power of 5-6 diopters or higher. Multiple high-grade myopia genetic loci have been identified in studies primarily performed in our laboratories. Confirmatory and additional studies identifying myopia loci have also occurred in other research laboratories. In general, myopia susceptibility genes are unknown with few association studies performed, and without confirmation in other research laboratories or testing of separate patient cohorts. Our international consortium is composed of myopia and statistical geneticists from the United Kingdom, France, Denmark, Australia, and the United States. Over the course of the past 8 years we have ascertained and obtained DNA samples on more than 250 family units primarily of Northern European descent with high- grade myopia. Within this international cohort, we have established significant heritability and/or familial aggregation for myopia. All of our samples for DNA are in hand and have been verified for genotyping. We gained approval for a single nucleotide polymorphism (SNP) genome screen at the Center for Inherited Disease Research (CIDR) of the National Institutes of Health to identify loci associated with the high-grade myopia condition. Mapping and association analyses are in process for the genotyping data provided by CIDR. Detailed plans for follow-up studies for established linkage intervals have been devised which include replication studies.
Our international myopia consortium represents one of the largest assemblies of families and cases with high-grade, sight-threatening myopia at an early age, carefully collected to document clinical phenotypes and related covariates. This unique and precious resource will be the basis for the proposed study of the genetic influences for exaggerated eye growth leading to myopic development. We hypothesize that the identification of myopia susceptibility genes will not only provide insight into the molecular basis of this significant eye disorder, but will also identify pathways involved in eye growth and development. This effort may lead to effective therapies to treat or potentially prevent this common eye condition.
|Lim, Sing-Hui; St Germain, Elizabeth; Tran-Viet, Khanh-Nhat et al. (2014) Sequencing analysis of the ATOH7 gene in individuals with optic nerve hypoplasia. Ophthalmic Genet 35:1-6
|Beekman, Marian; Blanche, Helene; Perola, Markus et al. (2013) Genome-wide linkage analysis for human longevity: Genetics of Healthy Aging Study. Aging Cell 12:184-93
|Lim, Sing-Hui; Tran-Viet, Khanh-Nhat; Yanovitch, Tammy L et al. (2013) CYP1B1, MYOC, and LTBP2 mutations in primary congenital glaucoma patients in the United States. Am J Ophthalmol 155:508-517.e5
|Young, Terri L; Hawthorne, Felicia; Feng, Sheng et al. (2013) Whole genome expression profiling of normal human fetal and adult ocular tissues. Exp Eye Res 116:265-78
|Tran-Viet, Khanh-Nhat; Soler, Vincent; Quiette, Valencia et al. (2013) Mutation in collagen II alpha 1 isoforms delineates Stickler and Wagner syndrome phenotypes. Mol Vis 19:759-66
|Hawthorne, Felicia; Feng, Sheng; Metlapally, Ravikanth et al. (2013) Association mapping of the high-grade myopia MYP3 locus reveals novel candidates UHRF1BP1L, PTPRR, and PPFIA2. Invest Ophthalmol Vis Sci 54:2076-86
|Soler, Vincent Jose; Tran-Viet, Khanh-Nhat; Galiacy, Stephane D et al. (2013) Whole exome sequencing identifies a mutation for a novel form of corneal intraepithelial dyskeratosis. J Med Genet 50:246-54
|McClements, Michelle; Davies, Wayne I L; Michaelides, Michel et al. (2013) Variations in opsin coding sequences cause x-linked cone dysfunction syndrome with myopia and dichromacy. Invest Ophthalmol Vis Sci 54:1361-9
|Tran-Viet, Khanh-Nhat; Powell, Caldwell; Barathi, Veluchamy A et al. (2013) Mutations in SCO2 are associated with autosomal-dominant high-grade myopia. Am J Hum Genet 92:820-6
|Abbott, Diana; Li, Yi-Ju; Guggenheim, Jeremy A et al. (2012) An international collaborative family-based whole genome quantitative trait linkage scan for myopic refractive error. Mol Vis 18:720-9
Showing the most recent 10 out of 35 publications


text:
Sandra is an energetic and dynamic speaker who loves to teach others how to bring simplicity and productivity into their home, office and life. We offer a variety of topics for your group /organization or you can ask how we can customize a presentation to suit your needs.Read More
Our specialists will efficiently organize any room in your home. Organization Lane can help you edit your unwanted items and create a more functional, clutter-free and comfortable living space.
Read more about our residential services.
Whether your business is home-based or at a separate location we will identify what's wasting your time or cluttering your work life. Let Organization Lane help you improve your productivity.
Read more about our business services
Contact us today for a consultation: 412.841.7169 or email@example.com
Organization Lane is led by Sandra Lane, a board certified professional organizer. Her team includes Kelly Herman, organization consultant and Elizabeth Helsel, photo-specialist. Want to learn more about who we are …
Read more about Our Team
Organization Lane provides valuable services for residential and business clients. Sandra is passionate about sharing her message with others through informative speaking engagements. We look forward to helping you reach your goals.
Read more about Our Services
Sandra is a Certified Professional Organizer, a high distinction in the organizing industry. In order to maintain her CPO status she continues to learn and earn educational credits and enjoys sharing her knowledge with her clients.
Read more about Sandra's Credentials


text:
Tag Archives: 510
Happy 510 Day from JNC
Just a reminder to cherish your Bluebird on this May 10, our day of 510s. Happy 510 Day from your friends at JNC.
Old Tokyo photos oozing with Japanese nostalgic cars
We recently stumbled upon a thread of old Tokyo photos on the architecture site SkyscraperCity. Though the focus was the buildings, we came for the cars. Just look at these pictures and dream of being amongst these machines when they were still new.
EVENTS: 2014 Nostalgic2Days, Part 03
Part 03 of our 2014 Nos2Days coverage comes from a new contributor, Brandon Kelley, a resident of Tokyo. He met up with David, who supplied Parts 01 and 02, after a 45-minute train ride to Yokohama. The two of them toured … Continue reading
EVENTS: 2014 Nostalgic2Days, Part 02
Welcome to Part 02 of our Nostalgic2Days coverage, as we make our way across the Pacifico Convention Center on Yokohama's historic waterfront. In this installment we'll see the displays kyuusha tuning houses, some of the famous cars that have graced Nostalgic … Continue reading
ART CORNER: The custom 1:24 models of Luis Aguilar, Part 02
We met Luis Aguilar at a local AE86 owner gathering and immediately had our brains melted by his astounding 1:24 scale plastic models. It wasn't just his tremendous attention to detail that caught our eye, but his highly accurate adherence … Continue reading
VIDEO: Jay Leno drives the Nissan IDx NISMO
Nissan has been parading their IDx concept cars all over SoCal recently, and this weekend they ended up in the garage of car enthusiast and comedian Jay Leno. Tonight Show prop master Greg Elliot joins the show once again with his … Continue reading
Mazda Cosmo Sport and Toyota 2000GT in this month's Hemmings
A Toyota 2000GT and a Mazda Cosmo 110s will both grace the cover of the upcoming April issue of Hemmings Sport & Exotic Car. The pivotal pair of shiro historic flagships was garnered together by our buddy and fellow J-tin enthusiast Jeff … Continue reading
NEWS: Street debut of the Nissan IDx Concepts
Over the weekend Nissan did something very unusual. They took their priceless, one-of-a-kind concept cars all over SoCal to meet the public face to face. This would've been a ballsy move for any concept, but for the Nissan IDx siblings, … Continue reading
NEWS: Nissan IDx production confirmed
A top Nissan exec has confirmed that the Nissan IDx will see production. As of yet it's unknown which one of the two concepts, the IDx Freeflow or IDx NISMO, will get the green light.
NEWS: Nissan IDx gets a nose job for North American debut
Remember how Nissan said the Sports Sedan Concept was going to redefine the marque's future design language? They wasted no time and have already given the Nissan IDx, unveiled in Tokyo less than two months ago, a facelift for its … Continue reading
ART CORNER: Japanese Nostalgic Legos
Apparently, building JNCs out of Legos is a thing. After stumbling upon a Toyota Celica built by -Kyusha-, we fell down the rabbit hole and discovered an entire subculture of nostalgics made of plastic blocks. Here are some of our favorites.
EVENTS: Yokohama Hot Rod and Custom Show
Step into Mooneyes' Yokohama Hot Rod and Custom Show and you might think you've stepped through a wormhole to 1960s America. Every style you can imagine, from high-boys to lowriders, is represented, including ones actual Americans no longer care about. Raked … Continue reading
BOOKS: Inside Shelby American by John Morton
We suspect that while most readers will be buying the new book Inside Shelby American to learn about Carroll Shelby, JNCers will be buying it for its author, legendary race car driver John Morton.
EVENTS: Tokyo Motor Show, Day 01
We've already covered the biggest reveal of the 2013 Tokyo Motor Show, and it was a doozie. But it wasn't the only thing to see at the wild and wonderful event that showcases what the automakers we know and love … Continue reading
NEWS: Nissan's IDx Freeflow is the Datsun 510 reborn
At the Tokyo Motor Show today, Nissan revealed the IDx Freeflow Concept, a car inspired by the legendary Datsun 510. It's a love letter to the hard core Datsun devotee, or even newfound fans born decades after the original ceased … Continue reading
MINICARS: Hot Wheels BRE Datsun 510, a Red Line Club Exclusive
On Tuesday at 9am Pacific Time, Hot Wheels will be releasing a limited edition, online-only version of the legendary BRE Datsun 510. Here's how to get yours. UPDATE: The car has sold out in a little under 2 hours. Better … Continue reading
EVENTS: 2013 Japanese Classic Car Show, Part 04 – Rolling Stock
Purists will be pleased. This year's JCCS had significantly more bone stock cars on display than any previous show. And they weren't of the standard variety of, say, a 2000GT or Datsun 312, though those were well represented. We're talking … Continue reading
EVENTS: 2013 Japanese Classic Car Show, Part 03 — Mad Tuning Styles
The Japanese Classic Car Show showcases a wide variety of makes and models, but perhaps even more diversity can be found in the subject of this week's QotW — the multitude of tuning styles. Not only are there differing genres … Continue reading
EVENTS: 2013 Japanese Classic Car Show, Part 02 – Diversity
The sheer size of this year's Japanese Classic Car Show was unprecedented. Organizers Koji and Terry Yamaguchi told us that registration filled up in just a matter of weeks and that there were over 100 people on the waiting list, … Continue reading
GRAND TOURING: Crossing the country in a bone stock Datsun 510
You thought you drove a long way to get to JCCS? Meet Randy Lewis. Earlier this month Randy purchased a barn find 1972 Datsun 510 in Bethlehem, Pennsylvania and drove it 2,500 miles to his home in Phoenix, Arizona. Then he … Continue reading


text:
1200 Reviews
$1000 Protection*
Perfect transaction A+++. Easy web site to use, part was in stock, super fast shipping, very fairly priced. Highest recommendation; excellent vendor
Control panel assembly     . please emai
Control panel assembly     . please email for price
Charbroil: 463840204
This part may fit other models. Please contact us if you require additional assistance.
Our warehouse is stocked full of parts for all kinds of appliances.
Questions? Just ask - No call centers!
We are a USA business based in Denver, Colorado and we stand fully behind our products and service


text:
Hunter Swanson
Hunter Swanson joined the Office of International Programs in August of 2012. Hunter attended Longwood University where he earned his B.A. degree in History in 2008 and participated in the Slovakia Scholars program. After graduation, he worked in the Office of International Affairs at Longwood University for 4 years as a study abroad and international student advisor. While working there, he earned an M.S. in Community and College Counseling, also from Longwood University, graduating in the spring of 2012.
He serves on the Harrisonburg International Festival Advisory Committee, is the current treasurer and former president of Virginia International Educators (VIE), and has served as a Learning Partner for the Alternative Break Program on trips to Peru and Guatemala.


text:
What: The Grove Craft Beer & Wine Festival
Where: The Grove, 1421 Milwaukee Ave Glenview, IL 60025
When: Friday July 17, 2015
Time: VIP 5:30PM, GA 6:30PM till 10PM
What: 35 Breweries, 70 Different Craft Beers & Wine to Sample
Live Music by: Draft Week & Smokin Train
Food: Glenview's Best Restaurants & Food Trucks
Tickets On Sale Now
The Grove Craft Beer & Wine Festival held in beautiful Glenview IL will have over 2,000 attendees who will sample craft beers and wines from more than 35 makers and over a 70 beers, ciders & wines.
Proceeds of this event provide the Grove Heritage Association (GHA) funding to acquire and preserve the quality of surrounding properties, securing a green and sustainable environment for generations to come, and to support special Grove projects. The Grove Heritage Association is the official citizen, not-for-profit support group for The Grove.
The Setting:
The Grove is a 143-acre nature preserve and National Historic Landmark. It is an amazing blend of history and nature,in an incredibly serene suburban setting just north of Chicago.
Lush green grass surrounded by forest and trails are home to some of the areas most historic buildings dating back to the mid-1800's, each of which makes a great setting differing greatly from the typical, parking lot brew fest.
Guests may explore the historic homes, a blacksmith shop typical of the 1800's, and a wildlife center with live animals, fish and reptiles.
The Festival will feature over 35 breweries & 70 different Craft Beers. Many will be great brews from the best Midwest Craft & Micro breweries and some from right here in the Chicago area.
Each GA ticket holder will get 20, 3 OZ beer samples; VIP ticket holders will get 25, 3 OZ. beer samples and will start one hour earlier.
Breweries that have already signed up as of 3-3-15: Atlas Brewing Company, Abita, Brooklyn Brewery, Coronado Brewing Company, Emmett's, Empirical, Finch, Founders, Kona, Lagunitas, New Belgium, Revolution Brewery Rogue, Sierra Nevada Brewing Co., Smylie, Sprecher Brewery, Two Brothers, Urban Chestnut, Widmer.
Great food will be provided by some of Glenview's best restaurants. (sold separately)
The event will be held at The Grove, 1421 Milwaukee Ave Glenview, IL 60025, just South of Lake Ave & just west of 294. Directions to The Grove: The Grove is north of Downtown Chicago located in Glenview IL, across the street from ABT Electronics and the Wyndam Hotel near the intersection of Lake Ave. & 294. For those of you that are driving to the beer fest we will have plenty of parking.
A separate sponsorship proposal package is available to all interested in further promotions for their companies and brands. Inquiries on sponsorships can be directed to email@example.com or by calling 936 647 7399.
Check out our The Grove Craft Beer Fest Official T-Shirt – Only $15. Purchase with your Fest Tickets.
Must be 21 to enter the event. The event is rain or shine. Under extreme conditions, we have the right to cancel the event and will notify festival goers via email.
Please drink responsibly. The festival encourages responsible drinking. Designated drivers are allowed admission at a discount and will receive unlimited free water.
There is convenient Uber & Taxi service plus the Metra train stops in downtown Glenview just a few miles from The Grove


text:
Ripoff Report | Complaints Reviews Scams Lawsuits Frauds Reported
Follow this link to perform an advanced search of the complete text of all reports for "vincent motor company"
Showing 1-2
As the leading consumer advocacy website, our technology is being continually upgraded to handle the volume of searches from consumers, the media, the authorities and millions of others from around the world. While we are always in the process of upgrading, our search results may not return all reports. This is only temporary and intermittent. If you are an attorney helping victims, the media, or law-enforcement, please contact us to have us run a complete database search to help your case or story.
| You are now on
Specific Search - narrowed down
|Click here to broaden search → Simple Search
|Title City, State
1, Report #1132323
Mar 20 2014
|vincent motor company Vince i was employed as a mechanic..since i started.ive been lied to..and been refused to be paid for my service...this man is a cheater and lier..stay away abilene Texas Author: abilene, Texas Auto Mechanics: vincent motor company abilene, Texas
2, Report #1077465
Aug 20 2013
|Vincent Motor Company and/or CCI Investments treating customers poorly after the sale of a vehicle Abilene Texas Author: Abilene, Texas Auto Dealers: Vincent Motor Company Abilene, Texas
Advertisers above have met our
strict standards for business conduct.


text:
Proscar Impotence
buy generic proscar online
But don't worry, I'm sure they'll have something else by then."
proscar costo farmacia
proscar cost per month
SHe has been a very good dog despite all her issues & she deserves the best we can do for her—and if that means medication that is what we'll do
where can i buy finasteride online uk
We have successfully trained him- he sits, shakes with his left or right paw(whichever you call), lays down, is potty trained, and doesn't chew on anything on his toys when we are around
buy finasteride 5mg canada
You can take it with or without food, and you can have up to 3 alcoholic drinks while using it.
proscar finasteride 5mg
buy finasteride 5mg canada
generic finasteride 5mg
get proscar prescription online
where to buy proscar for hair loss
proscar online canada
proscar 5mg for hair loss
finasteride online australia
I actually like what you've acquired right here, really like what you're stating and the way in which wherein you are saying it
get finasteride prescription online
If you are being treated for high blood pressure, keep using Coreg even if you feel well
5mg proscar hair loss
do i need a prescription for proscar
buy finasteride online
we are engaged in offering a wide range of Cefaclor Tablet that is formulated using high grade approved ingredients and sophisticated technology in accordance with the set of universal norms
proscar 10 mg
buy cheap finasteride
generic finasteride versus propecia
is propecia better than generic finasteride
online pharmacy finasteride 1mg
proscar results hair loss
generic finasteride online uk
5mg proscar
proscar 1mg precio
Well, I was incredibly stupid and thought I no longer needed medication and weaned off of Prozac last October
generic finasteride 5mg price
proscar 5mg uk
buy finasteride online usa
finasteride generic for proscar
purchase finasteride
cheap proscar canada
Hmm it appears like your website ate my first comment (it was super long) so I guess I'll just sum it up what I wrote and say, I'm thoroughly enjoying your blog
buy finasteride proscar propecia
I do the silliest things to try and keep myself going
buy finasteride online 1mg
purchase generic finasteride
Este medicamento en culas contiene lactosa
generic finasteride 1mg walmart
buy proscar 5 mg
order finasteride 5mg
I want to encourage continue your great work, have a nice morning
buy finasteride online paypal
Terrific article This is the type of info that are supposed to be shared across the web
proscar order uk
"Mainly diabetes, a ton of high blood pressure medicine
proscar finasteride 5 mg precio
In one of these genetic tests and transmits drug clindamycin gel online purchase data through a catheter placed in the uterus womb, specifically in the study.
proscar cost canada
These were symptoms they did NOT have before
buy finasteride 1mg
I'm having a look forward to your subsequent put up, I'll attempt to get the grasp of it
5 mg proscar hair loss
cheap generic finasteride uk
The items faculty run departed for reasons additional than "because I am departure to negative myself," although fill sometimes exercise that hon- est approximate and are not understood gravely
finasteride online canada
purchase finasteride australia
finasteride 1 mg online pharmacy
where to buy proscar in malaysia
propecia finasteride reviews
Should the physicians at the center give her the morning-after contraception, knowing that it may cause problems for the fetus?
proscar 5 mg reviews
Symptoms are subsiding slowly but lingering
generic finasteride 1mg cost
Abhngig von der Erregerart wirkt der Wirkstoff hemmend auf das Keimwachstum oder abttend durch Hemmung der Bildung lebenswichtiger Eiweie in den Bakterien
buy finasteride for hair loss
finasteride 5 mg tablets generic proscar
proscar 5mg hair loss for woman
The starting dose of the tricyclics should be low
is generic finasteride as effective as propecia
Common side effects include headache, diarrhea, nausea, gas, abdominal pain
how can i get a prescription for proscar
proscar 1 mg effetti collaterali
order finasteride canada
proscar 5 mg tabletten
generic propecia finasteride 1mg
proscar generic available
order proscar online
finasteride 5mg tablets generic proscar
finasteride online uk
buy finasteride uk
finasteride online india
proscar 5 mg hair loss women
Each of us has a different history of accumulating images, Apple teamed up directly with banks and retailers for Apple Pay
generic finasteride 1mg reviews
Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and some types of chronic heart failure.
low cost proscar
A lot of times it's hard to get that "perfect balance" between user friendliness and visual appearance
buy generic proscar canada
purchase finasteride
buy cheap proscar online
cost proscar
buy proscar no prescription uk
Like I said in another post, sometimes I wish I didn't start studying all of this, sometimes too much info is just that
proscar prescription drug
where to buy proscar online uk
finasteride 1mg generic price
purchase finasteride propecia
proscar prescription for hair loss
proscar inactive ingredients
get prescription proscar online
proscar ingredients
proscar price compare
where can i buy finasteride uk
proscar price walmart
proscar 5 mg
proscar buy online no prescription
buy finasteride 5mg online
There are a whopping 9 new Treasure cards in this set.
generic finasteride costco
generic finasteride 1mg price
buy finasteride online paypal
generic finasteride 5mg reviews
[url=http://www.purevolume.com/zovirax2jr]order zovirax cream[/url] If there was none of this magnanimity in war, we should go to war only when it was worth while going to certain death, as now
generic finasteride 1mg buy
purchase finasteride propecia
Some commonly reported side effects in clinical studies were headache, fever, vomiting, upper respiratory tract infection, abdominal pain, diarrhea, nausea, and itching
does generic finasteride work as well as propecia
Yesterday was day two without Lamictal and I threw up all day
cheap finasteride canada
Peak plasma concentrations of fluticasone propionate were achieved in 0.33 to 1.5hours and those of salmeterol were achieved in 5 to 10minutes.
cheapest finasteride online
order proscar canada
I didn't need it to be rushed..but it came quickly anyways
proscar impotence
buy generic finasteride 5mg
The goals of this project, that is, rapid onset of action, high selectivity for PDE5, enough safety based on short duration and PDE selectivity, were achieved by avanafil
where to buy proscar in australia
proscar generic drug
Patients should never take more Levlen than is recommended
finasteride online prescription
proscar causes impotence
cost of proscar 5 mg
finasteride online prescription
Bior amitryptylin od tygodnia, zaczam od dawki 10mg/noc (tak przepisa mi lekarz)
generic proscar for sale
finasteride proscar propecia price
no prescription proscar
In dogs, ciprofloxacin administered at 3 and 10 mg/kg by rapid infusion injection (15 sec.) produces hypotensive effects
how to get proscar prescription
proscar time results
order proscar uk
generic finasteride 1mg walmart
Allopurinol is considered a moderately safe drug, meaning if the treatment should be effective, most patients will handle the drug well, without causing any adverse reactions
propecia finasteride price philippines
Minocycline belongs to the class of antibiotics known as tetracyclines
generic finasteride 1mg reviews
Or jail (also at tens of thousands of dollars per year)
proscar generic finasteride
Cremeapply repthey said said said
proscar 10 mg daily
buy finasteride online usa
proscar 1mg australia
Read more on International Business Times


text:
Nclex 2013
0 hi I was RN in INDIA.
now i am in usa.
planning to take nclex rn in october 2013
i need tips to pass exam with first trial.
i am so nervous.
i m reading saunders review 5th edition.Is that enough?
stretagy for passing exam has been changed in april so would like to have tips to pass exam this year.
thnksAug 23, '13 by NurseNanci1I am also studying for my NCLEX I have heard good things about Hurst reviews it's a tad $$ though. Do you have an employer? You might check to see if they reimburse. My employer will reimburse me the cost of the test and any review I purchase.Jul 29, '14 by bhumipatel2004i do work as resident assistant PRN so they may not


text:
By Sonya Colberg, Senior Investigative Reporter
Amyris Inc. (NASDAQ:AMRS) has fallen victim to loan sharks wearing black hoodies, steel-toed boots and perfectly wicked sneers, its SEC filings suggest.
Now the California biotech's new filings show it's gotten stuck with a $25 million debt financing deal spiked with - don't you love the word - "covenants" so draconian they'll set your hair on fire.
Don't take TheStreetSweeper's word for it. Take the words from the company's recent filing with the US Securities and Exchange Commission. With that costly loan deal and others in its frayed coat pocket, poor AMRS is in such a fix, it may:
"…need to issue … discounted equity, agree to onerous covenants …"
Now, AMRS may be in an even worse fix as the company approaches its quarterly earnings call scheduled for Thursday, May 8. The company has reported worse earnings numbers over each of the past five quarters than those anticipated by analysts - and those experts expected earnings losses as bad as 29-to-45 cents. Analysts this quarter expect a loss of about 28 cents per share.
Insiders and others may feel their trigger finger quivering right now. AMRS is trading at about $3.35 per share, yet there are options as cheap as $2.15. With 76.4 million shares outstanding, an astonishing 54.7 million shares could potentially hit the market.
"The upside of any equity investor would be severely limited by these options," said an analyst who requested anonymity.
Despite all this - plus the fact that the CEO himself has eagerly sold off some $8.9 million worth of AMRS shares, and evidently has remained equally busy counting proceeds from his days as prior director of a dying biofuels company - AMRS chief executive, John Melo recently asserted that the company has quite the 2014 business plan.
Mr. Melo, however, forgot to tell investors the SEC-filing details of the business plan that form the company's exit strategy.
The business plan depends on brutal current collaborations and undefined, not-yet-identified collaboration and licensing deals that may:
"… require us to relinquish commercial rights or grant licenses … not favorable to us …"
The SEC filing goes on to spill another shocker: "going concern" language. AMRS wrote the investors-get-the-heck-outta-Dodge language this way:
"If we fail to secure such funding, we could be forced to curtail our operations, which would have a material adverse effect on our ability to continue with our business plans and on our status as a going concern."
Worse yet, the going concern language is in a delayed annual filing.
A delayed filing is always a red flag. But it's even more worrisome that AMRS was forced to file late because it was looking at "liquidity needs" and "contingency plans." AMRS had to somehow offer a way to attempt to dig out of massive indebtedness and a measly $15.8 million in revenue, or about half the prior-year figure.
Once AMRS finally got the annual report filed, it contained more language that rings ominously in investors' ears.
The report notes:
"(Our) debt agreements contain various covenants, including restrictions on business that could cause us to be at risk of defaults."
The Emeryville, Calif.-based company has accumulated a deficit exceeding $820 million in its efforts to turn sugar-chomping bugs - actually controversial genetically modified yeast - into micro-factories that use Brazilian sugarcane (a feedstock with an arguably negative environmental impact) to ultimately create products such as niche fuels (see this link or this one to TheStreetSweeper's story to learn about its unfortunately futile jet fuel effort) and cosmetics.
AMRS borrowed $25 million from Hercules Technology Growth Capital just a few weeks after TheStreetSweeper's warning in March that AMRS desperately needed money. The draconian terms force AMRS to pay 9.5 percent, or 6.25 percent above prime, and meet a rat's nest of performance covenants and requirements. And if AMRS can't cough up an "equity financing covenant," it must come up with another $10 million.
Not counting that overhanging loan, AMRS regulatory filings show it also faces a daunting pile of other contractual obligations, ranging from old debts to purchase deals to leases.
That's $24.8 million in those other obligations. All due this year.
It's becoming obvious why AMRS is obsessed with an exit strategy.
As it all comes crashing down, and if there's a funding hitch for AMRS, SEC filings say as early as "the second quarter of 2014", the company plans to begin cost-cutting efforts, such as:
* "Significantly reduced" new product and commercial development.
* "Suspend operations" at pilot and demonstration facilities.
But, particularly at this stage, the company obviously must focus on R&D - not cut it.
Pilot and demonstration facilities are also key, because the company currently produces only farnesene (it hopes to soon add another product) at its only production plant, which is located in Brazilian sugarcane country.
The filing note on Page 12 states the Brazilian plant production has been tough and costly, and it just may never prove economically viable. New possibilities rely on what pilot and demonstration facilities cook up, though even those offer no guarantee of being translatable to actual commercial production.
AMRS cuts its own throat if it is forced to cut R&D and suspend those operations.
With AMRS shoveling millions of dollars in obligations and scratching furiously for more loans to add to its mountain of debt, what do you suppose company insiders are doing?
They are selling company stock.
That's right. After the market closed April 23 - and after several weeks of stock price-friendly announcements largely devoid of meaning or details - company insiders filed notice with the SEC that they were holding their own private fire sale.
Company officers and directors have been privately selling a load of about 1 million shares of AMRS since April 14.
Yep, that's about $4 million right in their old overstuffed wallets.
Mr. Melo, who is named in two class action lawsuits alleging securities violations and making false and misleading claims in SEC filings, has really stuffed his wallet in the past three years.
Mr. Melo has sold about $8.9 million worth of AMRS stock.
He's drained his AMRS stock holdings - both directly and indirectly - down to little more than 240,000 shares, records indicate. He often sells his stock options as soon as possible - and they cost as little as 28 cents a share.
Just recently, Mr. Melo joined relative newcomer Susanna McFerson's lead as she dumped 49,841 shares in March in a non-market sale at $5.05 apiece for a cool $251,000. On April 1 and April 9, three fellow officers fetched $3.96-$4.44 per share in their sell-off of well over 330,000 shares.
Mr. Melo surprised investors last April Fool's Day with his non-open market sale at $4.44 each of 353,484 shares. He plumped up his wallet that day alone by about $1.6 million.
Maybe Mr. Melo and his fellow insiders have no more faith in AMRS than partner Total Energies Nouvelles ActivitA. We previously described how AMRS gave away the farm when it inked a joint venture to allow Total to exploit AMRS technology. Now it seems this partner distrusts AMRS so much that reports of AMRS cash, equivalents and short-term investments must be sent to Total every single month. And Total is so unsure of AMRS's future, that it holds tight to "No-Go" privileges that let it back out on its partner.
TheStreetSweeper is still waiting for a response to our March phoned and emailed requests for comment from AMRS.
Investors may find other viewpoints about AMRS here, including those of a blogger who owns shares of AMRS, writes for AMRS shareholder Motley Fool and is paid to write for SynBioBeta, which has AMRS' Tim Gardner scheduled as keynote speaker for the synthetic biology industry promoter's conference this year.
Despite AMRS' struggles, its chief executive does pretty well, with his salary and bonus alone running around $700,000.
And this isn't Mr. Melo's first rodeo - or his first big sell-off of his own company's stock. He got practice vigorously selling company stock as a director, along with former AMRS director, Ralph Alexander, for desperately foundering biofuels company, KiOR (KIOR).
On KIOR's perilous ride down from $20 stock in September 2011 to $12 stock four months later, Mr. Melo sold that biotech stock. This link shows the drastic stock price declines after Mr. Melo sold both KIOR and AMRS shares.
KIOR stock is now about 67 cents.
KIOR and AMRS share another unfortunate similarity. Despite getting a $100 million infusion just last fall, KIOR included in its March SEC filings a "going concern" issue. Much like AMRS.
AMRS has touted farnesene refinement product, squalane, that can be used to make facial creams, even bragging the company has locked up 18 percent of the market. The chief executive, Mr. Melo, said the peak market is about $180 million.
Something's wrong here.
AMRS sales were just $15.8 million. But Mr. Melo said squalane is just one-third of that. That's about $5 million.
But for AMRS to claim that much of the supposed market, the squalane revenue would have to be more than $32 million - that's over six times the company's squalane revenue.
The market is much smaller than Mr. Melo claims. Or AMRS' share is much smaller than he claims.
Either way, it's another huge, snapping red flag.
Add to that Mr. Melo's bold claim that AMRS can somehow boost the market to $300 million. We agree with the astonished analyst who asked, "How do you do that?"
The manufacturer that took six weeks to produce enough biofuel to fly a jet a few days has now cranked out some fiery news. And we do mean fiery.
AMRS announced it has begun selling its chemical farnesene online.
It's for anyone interested in acquiring their own stash of the chemical - at $595 per kilogram, or about $2,380 per gallon - so that customers can get creative. They can supposedly use it to make designer jet fuel, adhesive, resin, perfume or even a brand-new set of tires.
"We expect to accelerate Amyris's commercialization by simplifying access to high-purity, renewable farnesene," said CEO Melo.
Don't worry about the poor delivery guy who brings this highly flammable, highly toxic chemical to customers' doorsteps. It's hard to imagine Fed-Ex or the US Post Office agreeing to ship this dangerous hydrocarbon. But that's what AMRS would have investors believe.
If this online pitch is an actual strategy to sell more product, it's absurd. If it's a strategy to make investors think AMRS is trying to open up another doorway to commercialization, it's insulting.
The company's floating along primarily on collaborative funding and borrowed money. The loan sharks have already chomped, and more are breaking through the doors. AMRS doesn't need any more problems but, since our last article, TheStreetSweeper has dug up a quivering pile of them, including:
* "Going concern" language, delayed 10-K and overhanging shares foreshadow an even tougher road ahead - one that potentially includes an exit strategy.
* Announcement of online sales of farnesene sugar-chewing bug mix is ridiculous, insulting.
* CEO's claims of squalane market are exorbitant, misleading.
* AMRS works beneath heartbreaking toxic financing and collaboration deals that make it even harder to operate a business.
* The company struggles. Yet, the CEO and other insiders are sending signals to get out, we believe, as they sell multi-millions in AMRS stock.
The signs are all there. A knife is at AMRS's throat, and only a huge capital infusion can help this debt-riddled company now.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: * Important Disclosure: The owners of TheStreetSweeper hold a short position in AMRS and stand to profit on any future declines in the stock price. •Editor's Note: As a matter of policy, TheStreetSweeper prohibits members of its editorial team from taking financial positions in the companies that they cover. To contact Sonya Colberg, the author of this story, please send an email to email@example.com.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.


text:
My Dad and I are heading out to Unit 14 in CO (Routt National Forest) this year for our second Elk Trip in about 3-4 years. We aren't new to hunting, but definitely new to Elk and this particular area, and learned that our approach the first time around was not the best. We will not have the opportunity to scout the area like we would, except for about two days prior to the second rifle season. According to some scouting I've done through the computer and various maps, I've narrowed down an area but was wondering if any experienced hunters have been in the area and would have any advice or knowledge about the area. I'm not asking for your honey hole at all, b/c those are definitely rewarded through hardwork and would love to find our own, but just some good areas to start, or the elevation that they might be at during the second rifle season.
I was thinking the area a few miles East of Clark and North of Seedhouse Road. My next idea is to hunt the public fringes to the private land around that area, thinking that we might catch the Elk going between those two areas. We won't have any ATVs or horses, just our feet, and we aren't afraid to put in the miles either. The disadvantage to this is that we will be coming from Steamboat Springs area every day, and will not be camping out.


text:
Golden beaches, Six Flags and Hollywood are just a few of the hot spots that are only a short drive from this Canoga Park hotel.
The Ramada Limited Canoga Park is located in Canoga Park, approximately five miles from Universal Studios, 12 miles from Burbank Airport, and 20 miles
Beautiful property isolated from traffic with parking spaces in front of rooms. Pool and Jacuzzi. Free abundant Continental Breakfast. Free Wi-Fi and Business Center. HD TV's in most rooms. VHS & DVD Players. Recreation Center & Fitness Room.
Hollywood Hotel - The Hotel of Hollywood is Where All The Action Begins! Centrally located to all major tourist attraction and venues including Universal Studios, Walk of Fame, Hollywood Bowl, The Greek, The Los Angeles Convention Center, Downtown
" 99 Steps to the Beach..." Envelope your senses in the alluring tranquility of the infinite Pacific while you relax and rejuvenate in one of our newly remodeled, fully air-conditioned rooms featuring large, oversized whirlpool spas for two....
The Capri is finished with its room overhaul. From the new down linens and pillows, to our 42 inch plasma screens in every room. We have all non smoking rooms & pet friendly rooms. We have 2 pools,jacuzzi,free wifi, & continental breakfast.
In 1985, San Francisco Bay area designer Tom Brooks was commissioned to create an Inn from the existing structure of a historic 1940's California-Spanish style firehouse and Clocktower. Focusing on the Spanish influences predominant in the American S
OUR SPACIOUS GUESTROOMS WERE NEWLY RENOVATED. AAA 3 diamond rating.Best Western South Bay Hotel is located 4.5 miles from Los Angeles Intl. airport. We provide FREE 24/7 Airport Shuttle, wireless internet access, parking and CONTINENTAL BREAKFAST.
The Best Western South Bay Hotel in Lawndale, California located midway between Disneyland and Universal Studios where the staff is friendly, the accommodations are top-notch and the location is great. This Lawndale, California Hotel offers comfortab
*Days Inn -* Best rates, *Clean Luxury rooms. Swmming pool, Groups welcome.$59.00 One Bed, One or two persons, Must GTD reservation. 24 hrs in advance cancellation required. Group Accomodations & Govt Welcome. *Excellent Customer service.
Find great deals on quality hotels & resorts in Canoga Park California, or indulge at one of our luxury resorts. Take advantage of the many amenities that can be included with your stay such as in-room internet access, wifi, room service, fitness center, pool, hot tub, steam room, and shuttle services to and from the airport. Browse our hotels and resorts in Canoga Park California and plan your Canoga Park California vacation today!


text:
Jobs in Bolton Wood Lane
Email me jobs like this
Learning and Development Trainer
Posted 5 days ago by Story Contracting
Trainee Sales Consultant - Estate Agency Maternity Cover
Posted 10 January by Your Move
PA to the Finance Directors
Posted 5 days ago by Story Contracting
Posted 5 days ago by Well Featured
Care Worker
Posted 10 January by Mears Group
Physicist - Mathematician
Posted 5 days ago by Vector Recruitment Ltd
WBL Health & Social Care Assessor
Posted 6 days ago by GPRS Recruitment
Posted 13 January by Creative Support Ltd
Warehouse Operative - Carlisle MC
Posted 1 week ago by Angard Recruitment
Care Workers
Posted 19 December 2016 by Creative Support Ltd
Posted 11 January by Search Consultancy
Store Manager for an Established and Expanding retailer
Posted 3 January by Zachary Daniels
Estate Manager, Carlisle
Posted 19 December 2016 by Hanover Housing
Sign in to create your email job alert.
Replace a saved search
Replace a saved search
Shortlisted job limit
You have reached your limit of 100 shortlisted jobs. To save more, please delete some of your existing shortlisted jobs. View shortlisted jobs


text:
Redwood City, CA 94062
I enjoy all aspects of internal medicine. My goal is to practice evidence based medicine, be a good listener and give my patients the time they need. Read more
For the best healthcare for your needs, choose a doctor who specializes in your medical condition.
Board certification indicates that a doctor is highly qualified in the medical field in which they practice.
Check to see that this provider treats your medical condition.
Check to see that this provider performs the procedure that you need.
Check to see if your provider has any malpractices, board actions, or sanctions.
Learn more about where this provider went to medical school, residency, and more.
View information about special awards and recognition for this provider.
Check to see what languages this provider and/or staff speak.
View memberships and affiliations associated with this provider.
Likelihood of recommending Dr. Aron to family and friends is 3.7 out of 5
Check out the quality of care at the 2 hospitals where Dr. Aron has admitting privileges.
Internal Medicine Specialist
Internal Medicine Specialist
Internal Medicine Specialist
Internal Medicine Specialist


text:
With outstanding products and services we provide tactical advantage to the operator.
Patriot3 Maritime (P3M)
Innovative, state of the art specialty equipment for the maritime operator.
Protective clothing for military, police and fire fighters. Designed to protect
VDL integrates SoundCommander in Dutch Crowd & Riot Control Vehicle
The Dutch National Police has ordered 300 Crowd & Riot Control Vehicles after an intensive selection process. The new white vehicle is a replacement for the blue VARIO which has been in service for more than two decades. In the fall of 2016 the first white...read more
Libervit introduces next version lightweight hydraulic breaching tool
For many years our customers have been working with a large variety of Libervit hydraulic breach tools under which the lightweight OP53. During those years the tool suggestions for improvement have been put forward by many units. After a short development period the...read more
Apex Global is specialized in high quality products and services for special forces and military organizations. Founded in 1999 Apex Global operates as a distributor via its reseller network, as well as through its sales organization in The Netherlands, for a small range of high quality products.


text:
Credit funds end strong first half on a high
Credit-focused funds were among the best performers in June, ending a strong first half of the year on a high note.
It was a bumper month for Trafalgar Recovery, which put on 9.45% in June and is now up a hefty 28.48% for the first six months. Mark Benson's Ravenscourt Multi-Strategy Credit gained 8.56% for a year-to-date return of nearly 18%.
Cheyne Total Return Credit was up 6.75% for a whopping three-month gain of 36.39%, while GLG Loan is up 30.19% so far this year after gaining 3.39% in June - although it is still down by some


text:
I agree chrisgal, completely baffling and wish I had not kept watching the past 4 weeks!
Im still confused who got away and who got caught?
|Best Answer
For more on marking an answer as the "Best Answer", please visit our FAQ.
I agree chrisgal, completely baffling and wish I had not kept watching the past 4 weeks!
Im still confused who got away and who got caught?
So it was persistent or long-lasting then ?
Didn't see/hear it myself so couldn't comment on its quality I'm afraid.
[all right, I'll get my coat]
Was the end cr?p, have got it taped, thought it had been good these few weeks, just waiting for the grand ending.
Must agree, dreadful end to an otherwise fairly enjoyable story, just a bl--dy awful way to end.
I agree with all of the above, very disappointing end. Oh well!
Glad I saw this. I have recorded all episodes but so far haven't had a chance to watch any - I was going to do a marathon when I had a spare afternoon.
In light of what has been said, I'll just erase the lot now unseen.
I too had loved the series, but the very end didn't make any sense to me, I'm not sure what was suppose to be going on.
It's a shame, it had been a great series up until then.
terrible ending to a great mini series
I agree, I was very disappointed.
Hmmmmmm.......initially I was disappointed with the ending but having mulled it over I can see that it was in-keeping with the story-line.
Although, I think a more dramatic ending would have left me feeling more satisfied for my 'investment' of time and concentration.
I'm really disappointed at the ending - it seems like they didn't know how to end it, and I found all their tooing and fro-ing between months confusing as well. However, I'm looking forward to going to ITV player and watching the Trevor Eve - kidnap thing this afternoon.
I really enjoyed it.
Question Author
well, i think everyone's done really well to not say actually what happened (for those who haven't seen it yet)!
Hubby says they've done it that way so they can do a second series.
i do feel cheated though.
yeah, I totally didn't "get" the end either.
Just seen this thread and agree with everybody. The ending was rubbish after watching for 4 weeks!
Is there a possibility that the writer was found dead at his keyboard and a cat had been walking over the keys for hours?
On second thoughts, that result might have been better.
Of course it coul just be art and we've all missed it. :P
Well I suppose it was a different ending, normally there is only two possible outcomes to a robbery drama, so the fact that they found a third way was at least unusual imo.
Related Questions
|Hi all! Yesterday I came home from work to find two of my neighbours (from separate houses, men in their 30' & 40's) in our back garden attempting to get one of the neighbours drones out of our tree...
|W.H.Smith are advertising free cinema tickets for the new X Men The Last Stand movie released 26/05/06. if you buy one of the first two X men DVDs. i have just bought Xmen1 as we didn't have it on...
|Save The Last Dance is a good film and I love the music in it but there is a particular song in it I like and I cant find that song anywhere on the internet. Can anyone help me??? The song comes on...
|Last one but suspect I may have something wrong, Clue: trimmed soldier ran about inside (5) I have G-r-i...
|Last one, clue: showy agent has no right to go inside (6) I have: a-o-t- Thanks in advance....
|fell asleep and missed some of the last episode...woke in time to see boss man driving back to depot with the loot and the chap with the gobby gf driving off ??? did any of them get away with it ?...
0 min ago
It's Been A Great Day So Far ...
2 mins ago
Trump's Alternative Facts !!!!
5 mins ago
7 mins ago
Where Can I Buy Designer Shirts For Men?
29 mins ago
Dog Fights Prompt 5,000 Calls To Rspca...
30 mins ago
Animals & Nature


text:
Depomed, Inc. (NASDAQ:DEPO)
Q2 2008 Earnings Call Transcript
July 31, 2008 5:00 pm ET
Ina Cu – IR
Carl Pelzel – President and CEO
Tammy Cameron – Controller and Interim Principal Accounting and Financial Officer
Mike Sweeney – VP, Product Development
Andy Schopick – Nutmeg Securities
Scott Henry – Roth Capital
Good day, everyone, and welcome to the Depomed second quarter 2008 conference call. Today's conference is being recorded. At this time, I would like to introduce Ms. Ina Cu. Please go ahead.
Ina Cu
Thank you. Good afternoon. This is Ina Cu, and with me today are Carl Pelzel, President and Chief Executive Officer; Tammy Cameron, Controller and Interim Principal Accounting and Financial Officer; and Dr. Mike Sweeney, Vice President of Product Development. At the close of market today, we issued our financial results for the second quarter ended June 30, 2008. The purpose of this call is to expand on the contents of our press release, provide an update on our business, and to provide financial guidance for the remainder of 2008.
Before we begin, I'd like to remind you that during this call we will be making forward-looking statements related to various aspects of our business, including statements related to clinical development, financial matters, and commercialization of our marketed products. Actual results may differ materially from the results described. We encourage you to review the risk factors in our most recent quarterly report on Form 10-Q.
I will turn the call over to Carl Pelzel.
Carl Pelzel
Thank you very much, Ina. Good afternoon and thank you for joining us for our second quarter 2008 conference call. I would like to start with a few comments regarding the state of the pharmaceutical industry, which I believe is continuing to evolve in a manner that strongly validates our business model. Now, more than ever, new chemical entities are not an automatic route to success as managed care, physicians, and patients insist on meaningful product differentiation.
A good example of this is GSK's initial withdraw of their application for an extended release version of Requip after the FDA questioned its clinical benefits compared to immediate release Requip. As line extensions with little differentiation are called into question, big pharma's enormous investments in new chemical entity development programs are becoming more risky. As you know, there are numerous examples of the many pre-approval and post approval risks in the NCE model.
In contrast, our model of developing known chemical entities has proven to be far less costly and less risky since we identify a target profile in advance, using a compound with a long established safety record, and then move our programs forward with a higher degree of confidence in our ability to meet that profile. While big pharma's response to the new challenges in our industry is somewhat fragmented, I think that the industry's recognition of the need for meaningful differentiation is reflected in GSK's recent request that several European health agencies rank GSK's early stage product pipeline to get a sense if the products would be reimbursed and to understand what data would be needed for reimbursement.
Another good example is Pfizer's recent announcement at a health care conference of its intention to become a world leader in product enhancements and reformulations. Now, I don't mean to suggest that we won't ever consider developing or acquiring NCEs under the right circumstances, but I am pleased to see the industry paying more attention to the need for therapies that benefit patients and payers alike regardless of whether they happen to be NCEs or not.
Let me now move to our business review. We are pleased with our financial performance this quarter, which is the result of our prudent control of our expenses, non-dilutive access to capital, and the execution of cash-generating milestones. Our current financial profile enables us to negotiate from a position of strength with potential partners, increase the value of our key company assets, and avoid dilutive financings in an environment where access to capital is restricted.
We strengthened our cash position in the first half of 2008 with a $10 million cash and royalty settlement of our patent litigation lawsuit against IVAX, a credit facility of $15 million from Oxford Finance and GE Capital, and the $12 million upfront fee from the Glumetza promotion agreement with Santarus that we received in July.
With the Glumetza deal behind us, we focused our business development team on partnering our Gabapentin programs and our development group on the execution of our three value-creating Phase 3 registration trials for Gabapentin GR. The first trial is the PHN trial we started in March of this year. The other two trials support our hot flash program and were discussed with the FDA during our end of Phase 2 meeting in June. We anticipate starting the first Phase 3 trial in menopausal hot flashes in the third quarter with the second trial beginning early in the fourth quarter.
As we described in our last quarterly conference call, the company is focused on five key objectives this year. Two of those objectives have already been achieved. We've partnered Glumetza and we've settled our patent litigation lawsuit against IVAX. The three remaining objectives are to rigorously manage our cash position, to partner and develop our two Gabapentin registration programs in PHN and hot flashes, and lastly, to advance our early stage pipeline.
Our current cash position is strong, and we plan to keep it that way by controlling our expenses and executing on additional cash generating milestone events. We ended 2007 with $69.5 million in cash and ended the first half of 2008 with $71.2 million in cash. In this quarter, we have already brought in an additional $12 million from our Glumetza deal with Santarus and we drew $5.6 million under our credit facility just today. So we have more than doubled our cash over the last four quarters without diluting our shareholders or compromising our late-stage Gabapentin GR development programs, which we see as near-term value drivers. It is important to note that we evaluate our use of cash and our need for cash not on a six-month horizon, but strategically on a three-year forward-looking window.
Now let me review our progress to date on our Gabapentin GR programs in PHN and in hot flashes. In June, we had a successful end of Phase 2 meeting with the FDA, in which we achieved agreement on the design of our Phase 3 registration program for Gabapentin GR in menopausal hot flashes and the doses to be tested. Based on these discussions and the resulting program design, we are able to revise downward our projections for the cost of these trials, which I will address at the end of the call.
The program, which we anticipate will begin in the third quarter, will include two randomized, double-blind, placebo-controlled studies of approximately 540 patients per study. The design of a program is consistent with the FDA's guidance on vasomotor symptom studies, which includes recommendations as to the study duration, primary efficacy end points, and inclusion and exclusion criteria.
In each study, patients will be evenly randomized into three treatment arms. The first group receives placebo; the second group, 1200 milligrams of Gabapentin GR dosed once daily at night with the evening meal; and the third group, a total dose of 1800 milligrams of Gabapentin GR dosed 600 milligrams in the morning and 1200 milligrams in the evening.
The treatment duration in the first study, let's call it study A, will be three months in order to assess the frequency and severity of hot flashes after four weeks of stable treatment and then again after 12 weeks of therapy. The second study, study B, will be the same as the first with efficacy measured at four weeks and 12 weeks. But in addition, this trial will be extended by a second three-month period in order to assess the persistence of efficacy at six months and to collect additional safety data.
As I just mentioned, the primary efficacy end points in both studies will be reductions in the mean frequency of moderate to severe hot flashes and the average severity of hot flashes in both cases after four weeks and 12 weeks of stable treatment. Various other secondary efficacy end points will be measured as well.
Regarding the active arms and the efficacy end points, the 800-milligram dose was the dose with the optimal balance of efficacy and side effects in the Phase 2 trial. And the 1200-milligram dose was the lowest dose showing a trend toward efficacy with low side effects in our small Phase 2 study. If the results of the Phase 2 trial are repeated in these two large studies, both doses will show statistical improvement over placebo.
Now, assuming a patient population similar to the patients in our Phase 2 trial, we estimate that the studies are powered to detect statistically significant differences relative to placebo in the frequency of approximately two moderate to severe hot flashes per day over placebo after both four weeks and 12 weeks of steady dose therapy.
Meanwhile, the Phase 3 registration trial in PHN that we started in March is progressing well. As a reminder, the PHN study is a 450-patient placebo-controlled double-blind trial with a ten-week stable treatment period. Now, as we have discussed, the new trial includes a number of important differences relative to the previous PHN trial. First, the new trial has a single 1800 milligram once daily active arm and will enroll 450 patients or about 50 more than the previous trial.
The additional patients and the single active arm mean that the new trial is statistically powered to achieve significance at a difference of 0.4 on the Likert 11-point pain scale rather than the 0.7 in the prior study. Also, patients are only eligible to participate in the trial if they recovered from shingles at least six months prior to enrollment rather than the three months as they were in the previous trial. The new eligibility criteria are designed to enroll a more stable patient population.
Furthermore, we are including clinical sites in Russia and Argentina in addition to the US sites to accelerate enrollment and also possibly to recruit a more symptomatic population of patients. We have just screened the first patient in Russia this week. So we will need some visibility into X US enrollment rates before we are in a position to provide meaningful guidance as to the completion of enrollment for this trial.
On the partnering front, discussions for our Gabapentin programs are ongoing and we are pleased with the parties at the table. Due to the sensitive nature of those discussions, we will not disclose timing or other details of any potential deal at this time.
Now let me walk you through our latest cash generating milestones. As you may recall, our promotion agreement with King was terminated in the fourth quarter of 2007 when King lost IP protection on Altace a year before they anticipated it might occur. We were able to negotiate a termination fee with King that totaled almost $30 million. Our intention at that time was to implement our own sales and marketing activities sufficient to keep the product prescriptions stable while we look for a new partner. We accomplished this.
TRx's for October of 2007 were 20,991 and TRx's for June of 2008 were 20,148, while Glumetza's market share in the branded metformin market increased from 19.5% to 22.2%. We also kept for ourselves all the Glumetza revenue, which has contributed to the low burn rate we have seen beginning with the fourth quarter of 2007.
Now, we set out to find a new partner for Glumetza with some very clear objectives in mind. Early in the process, we characterized the type of deal and partner we were seeking to sign. We expected an upfront payment and we wanted a partner with a strong sales force committed to the success of the product. We also wanted to avoid just being one more product in the salesman's bag. We also wanted to continue our own increasingly ownership of this valuable asset by booking sales and managing contracting.
The Glumetza transaction we did earlier this month with Santarus meets those requirements. We received $12 million in upfront fees and may receive up to $16 million in additional sales milestones. While we continue to book revenues from Glumetza, we will pay Santarus a gross margin split of 75% to 80% of the margin beginning in the fourth quarter. Glumetza will be promoted by 300 highly motivated sales representatives who have been honing their skills in the highly competitive PPI market with Zegerid. This is the perfect time to bring on a motivated team of 300 sales representatives, now that we have launched the 1000-milligram tablet of Glumetza in June and have made significant progress on the managed care front, as previously reported.
With Santarus beginning promotion in the fourth quarter, we will end our agreement with Publicis regarding their 33 part-time sales representatives. The deal with Santarus makes sense for us because it maximizes our near-term cash flow from Glumetza and reduces our sales and marketing expense exposure. While we were fortunate enough to be able to maintain Glumetza's run rate, about $20 million in annualized sales during the first half of 2008 with only 33 part-time sales reps, new prescriptions have started to decline. We think that decline would have impacted Glumetza sales at some point without a real increase in the sales and marketing effort behind the product.
Launching our own sales force or expanding a contract sales organization while continuing to wholly fund the marketing efforts by ourselves would have been very expensive. Glumetza is an important part of our business, but our late-stage Gabapentin GR programs are much bigger drivers of near-term value for our shareholders. So we did not want to take on all the risk and distractions associated with the infrastructure and execution necessary to make Glumetza a bigger success without the help of a partner.
With the Santarus deal, Santarus is responsible for the cost of their sales force and all marketing expenses. This removes the sales and marketing expense risk we would have if we continued to sell Glumetza alone. As a result, we reduced our exposure to Glumetza sales performance with a $12 million upfront, but we keep all of the third quarter Glumetza revenue and a fair share of the ongoing gross margin stream. But we get immediate cash and participate in the future success of Glumetza.
In June, we secured a $15 million non-dilutive credit facility from Oxford Finance and GE Capital. We have borrowed $9.4 million under the facility and we expect to draw down the last tranche of $5.6 million by September 30. We borrowed this money after setting out last fall to secure non-dilutive financing during a period of restricted access to capital and important partnering discussions. We wanted to make sure that we had the cash to focus on and advance our hot flash program without eroding our negotiating position with potential partners.
The credit facility accomplishes all of that and more. It serves as an insurance policy to protect us against downside risks, such as further tightening of the capital markets, and also provides us with operational flexibility. We plan to draw the full amount for all of those reasons and because we think the terms are very favorable. It would be unlikely for us to get similar terms in today's worsening credit markets.
In April, we settled our patent litigation lawsuit against IVAX. In that settlement, we received $7.5 million one-time payment and will receive up to $2.5 million in royalty payments from IVAX's parent company, Teva, on future sales of generic Glucophage XR by both IVAX and Teva.
Other positive developments on the IP front include the recent allowance of a Gabapentin GR patent application in the US, which marks our third patent allowance of the year and extends the protection for Gabapentin GR out to 2024. As to our early stage pipeline, our goal is to move one preclinical program into Phase 1 this year and another early next year. These new programs promise to have a high degree of product differentiation that will be meaningful to patients, physicians, and managed care, just like our Gabapentin GR programs.
One of the programs is our preclinical Levodopa/Carbidopa program, which we recently disclosed after the award of a grant from the Michael J. Fox Foundation. We are very enthusiastic that our technology might hold the potential to improve the lives of Parkinson's patients and appreciate the recognition we received from the Michael J. Fox Foundation.
Levodopa/Carbidopa is a gold standard therapy for Parkinson's disease. However, due to the preferential absorption in the upper GI tract at the duodenal cap, current formulations fail to optimize absorption, which potentially leads to blood level fluctuations, which in turn may be responsible for debilitating side effects and very inconsistent efficacy. We started the program under the hypothesis that the delivery of levodopa could be significantly improved with our AcuForm technology, which could optimize levodopa's absorption at the duodenal cap and smooth out blood fluctuation levels.
Currently, patients whose drug levels fall during the night can wake up in a frozen state where it's hard for them to move. Our belief in this program is based on part on dissolution testing conducted with our formulation compared to the market leader formulation Sinemet extended release, wherein our formulation demonstrated a much smoother release profile over a four to six-hour period while Sinemet CR was rapidly released within about an hour.
Regarding ProQuin XR, we are pleased that our partner Rottapharm/Madaus has received marketing approval in Sweden, which serves as a reference member state for further regulatory approvals in Europe through the mutual recognition procedure. Our European partner, Rottapharm/Madaus, expects to launch ProQuin under local trade names in various European countries throughout 2009. This concludes our business review.
And I'll now turn to financial matters. Our cash position increased in the second quarter by $7.5 million. Our cash burn for the second quarter, excluding the $7.5 million from IVAX in April and excluding the $3.8 million we drew down in June from our $15 million credit facility, was only $3.5 million compared to $10.4 million in the second quarter in 2007 or $5.8 million in the first quarter of this year. We do anticipate our burn to increase in the third and fourth quarters of 2008 in conjunction with enrollment of the PHN and hot flash trials.
For the second quarter of 2008, we've recognized $5.5 million in product sales, most of which as you might imagine were Glumetza, compared to $5.2 million for the prior quarter ended March 31, 2008 and $2.5 million for the second quarter of 2007. Operating expenses for the quarter ended June 30, 2008 were $2.4 million, including the offset from the one-time gain on the settlement of the IVAX lawsuit of $7.5 million. This is compared to $12.6 million for the prior quarter ended March 31, 2008 and $12.5 million for the same quarter in 2007. The decrease in operating expenses in the quarter ended June 30, 2008 compared to the same quarter in 2007 was primarily due to lower costs associated with clinical programs, lower headcount cost associated with the reduction in workforce in the third quarter of 2007, and lower litigation costs related to the IVAX lawsuit.
For the second quarter of 2008, we reported net income of $3.5 million or $0.07 per share compared to a net loss of $9 million in the second quarter of 2007 or $0.20 per share. The net income in the second quarter is primarily due to a decrease in operating expenses driven by a one-time gain of the $7.5 million from the IVAX lawsuit. Cash, cash equivalents, and marketable securities as of June 30, 2008 were $71.2 million compared to $69.5 million as of December 31, 2007. Cash, cash equivalents, and marketable securities as of June 30, 2008 do not include the additional $12 million we received in July from Santarus or the $5.6 million second tranche of our credit facility.
As I mentioned earlier, we are revising our expense guidance downward for the full year. On our last earnings call in May, we indicated that we expected our SG&A expenses, excluding any profit share fees related to our promotion arrangements, to be in the range of $24 million to $28 million and our R&D expenses to be in the range of $35 million to $40 million. The new SG&A guidance is now in the range of $22 million to $25 million, excluding any profit share fees due to Santarus or Watson under our current promotion agreements. This is lower due to our expense reduction efforts, settlement of the IVAX case, and with the Santarus deal in place, we will no longer have marketing expenses starting in the fourth quarter.
The new R&D expense guidance is now in the range of $28 million to $33 million, just to remind you, down from $35 million to $40 million. Approximately $10 million is expected for the Gabapentin GR Phase 3 trial in PHN and approximately $5 million is expected for the Phase 3 program in hot flashes, and those figures are for 2008. Our R&D expense guidance is lower due to our expense reduction efforts and lower projected costs for the hot flash Phase 3 trials due to the clarity around those trials that came out of our end of Phase 2 meeting in June.
And with that, operator, we'd like you to please open up the call for questions.
Question-and-Answer Session
Thank you. (Operator instructions) We'll take our first question from Andy Schopick with Nutmeg Securities.
Andy Schopick – Nutmeg Securities
(inaudible) over Depomed. I do want to ask you a question about this credit facility. And although you have characterized it as non-dilutive and I guess in the sense that it doesn't involve any additional share issuances, it's at a very high interest cost, higher than I would have guessed would have been necessary in the environment. This facility is going to cost you about plus $1.7 million a year once it's fully utilized. What are the terms for prepaying any or all of this? And what are your intentions really with respect to trying to reduce the interest rate component associated with this financing?
Carl Pelzel
Yes. Thanks for the question, Andy. We didn't hear the first part of your comment, but I didn't think it was relevant to the question, so I won't ask you to repeat it. Let me first address what we are going to use this for. Looking ahead three years, we see that there is a major series of events when we receive approval of both the hot flash product as well as the PHN product. And with our stock where it is and with the current capital markets where they are, we felt it prudent to gain access to additional cash. As far as what we intend to do to reduce the interest rate as we go forward, we intend to draw down the last tranche before September. And so, our ability to reduce the interest would be based on whether we want to pay the loan off early, and we're going to have to see how our cash position progresses and how our need for cash changes over time. Let me ask Tammy Cameron to address the prepayment penalties.
Tammy Cameron
Yes. Andy, there is – on this debt facility, there is a 3% to 5% prepayment penalty depending on the timing and there is a 2% unused line fee.
Andy Schopick – Nutmeg Securities
Okay. You are going to utilize a lot so that won't come into play here at all.
Carl Pelzel
Andy Schopick – Nutmeg Securities
Okay. Secondly, with respect to the Santarus deal, I was on the Santarus conference call when this was announced and they revealed that the gross profit margin on Glumetza is a very attractive 83%. And obviously under the terms of this arrangement, they are going to capture 70% to 75% of all gross margin dollars associated with Glumetza sales. I just, again, would like to question why management felt it necessary to give away as much of the profit potential associated with any future Glumetza sales because certainly you are a lot further along with that than you are with the Gabapentin situation right now.
Carl Pelzel
Yes. We see that Glumetza has tremendous potential in the diabetes market. When you compare the product profile of Glumetza against Fortamet and you compare it to other products that are available for patients, we think the potential is great. And simply milking the product, letting it sit there and keeping all those revenues to ourselves, we feel would not enable us to maximize the opportunity Glumetza has. We see very significant sales potential. However, that can only be realized with the large sales force, 200 to 300 people that are highly motivated, very aggressive, and significant marketing budget. So, we don't see the $20 million run rate as representative of Glumetza's potential. We see that as the starting point. And the value we see in the product is in the sales increases we expect to see going forward.
Andy Schopick – Nutmeg Securities
Once again, my point being that a lot of the gross margin dollars are going to Santarus.
Carl Pelzel
As it has to. If you expect a company to bring forward and focus a 300-man sales force against a product, they have to be reimbursed for that.
Andy Schopick – Nutmeg Securities
They are going to be. My only other question here is really getting a sense of what – how one would model this company's revenue potential over the next three to five years because it's still a lot of things have been juggled and changed over the last two years; agreements that were put in place, that were terminated, and so on and so forth. So it's kind of a work in process and it's just real hard to get your hands around what the opportunity is going to be here.
Carl Pelzel
I guess a couple of components. Number one, we have plenty of cash. One, I do not see any kind of dilutive financing out beyond 2009 certainly. Secondly, most of the value in the company I feel is focused on Gabapentin, the PHN program and the hot flash program. And I think modeling significant amount of our value around those near-term events makes a lot of sense. I think it's looking to our pipeline products, the omeprazole program certainly has the potential to bring significant product differentiation into a highly competitive market and it has a clinical difference. It's just not a once-a-day product. And now the Levodopa/Carbidopa opportunity has the potential to increase clinical efficacy in an area of high unmet needs. So I would put most of our value on those near-term events.
Andy Schopick – Nutmeg Securities
Okay. Thank you.
Carl Pelzel
Thank you, Andy.
And we will move next to Scott Henry with Roth Capital.
Scott Henry – Roth Capital
Thank you, and good afternoon. I guess just starting – first, the decision to start the hot flash trial in Q3 versus waiting for a partnership agreement, at least on one of the indications, any thoughts on that? I mean, in theory you could start moving in both trials and a partnership could get delayed and it becomes a heavy investment. Just any thoughts on that process?
Carl Pelzel
Yes. Back in September of last year, we knew that the hot flash opportunity was going to be significant in and of itself, but very specifically for us because, as we've indicated previously, we intend to participate to a very large extent in that commercial opportunity with a small sales force in the 2010, 2011 time frame. So, timing was very important. In addition, recently we have seen that Lyrica's hot flash program, or Pfizer's program with Lyrica, has been terminated and Pristiq is running into trouble. So, timing is absolutely critical if we want to capitalize on the value associated with this opportunity. I will ask Mike Sweeney to talk about the strategy behind spacing [ph] the two trials slightly and not starting them at the same moment.
Mike Sweeney
Again, one of the reasons we chose to move ahead was that we had a very positive meeting with the FDA, and the FDA are obviously following the women's health initiative looking for to approve medications for the non-hormonal treatment of hot flash. These are two very large studies. And what you need to do is start one, have all of your investigators lined up, everything moving, all the systems tested, and then start a second a month later. And that will allow you an overall quicker update and movement on your studies. If you try to start them both at the same time, you risk even more delays. So we think that the optimum way is to start one in the third quarter and start the second about a month or so later.
Scott Henry – Roth Capital
Okay. Thank you. And perhaps a more specific question. You really divulged a lot about the trial design. If I heard correct, there would be a 1200-milligram once-a-day arm and an 1800-milligram that was split 600, 1200 morning, evening.
Carl Pelzel
That's Correct.
Scott Henry – Roth Capital
And will there be any escalation in those arms?
Carl Pelzel
No, there won't be.
Scott Henry – Roth Capital
Now, if I recall correctly, the Phase 2 trial did have escalation as high as 3000 milligrams. Do you have any concerns that you might have under-dosed this trial? And particularly if you have to – let's say, the 1800 milligrams is a successful arm, is the product less appealing as a twice-a-day product?
Mike Sweeney
No, just to – I'll take [ph] this question. Just to refer you back to our press release when we announced the results of the Phase 2 study that we did not see evidence of greater efficacy above 1800 milligrams. I would mention to anybody that we will be presenting the data more fully at the North American Association of Menopause in Orlando in September. So, the post will be available on our website immediately after that meeting.
Scott Henry – Roth Capital
Okay, that should be helpful. And could you talk a little bit about how the 1200-milligram – I'm just looking at – I believe there was a 1200-milligram once-a-day arm in the Phase 2, obviously less number of patients, but how was the trend in that arm?
Mike Sweeney
That was a positive. The study was a titration study. The 1200-milligram once-daily was only in the first six weeks. So we have to project out the results based on the first six weeks of the study. And they indicate, as Carl mentioned in the briefing, that we should see with these patient numbers not trend statistically and clinically significant efficacy. In addition, this was also associated with very low instance of side effects.
Carl Pelzel
So, Scott, we are really hedging our bets. In other words, we know in the study that the 1800 milligrams b.i.d. works, worked exceedingly well and seem to represent the top of the dose response curve. So that's – I can't say a given, but we feel very strongly about that, as did the FDA. But certainly we would expect once-a-day dosing with the 1200 milligrams to have fewer side effects, and based on what we saw in the Phase 2, to Mike's point, should work based on the larger number of patients in these two trials. As you may recall in the literature, 900 milligrams has worked in a number of trials. So we feel really good about the 1200, but wanted to hedge our bets with the 1800.
Scott Henry – Roth Capital
Any reason why you wouldn't hedge with an 1800-milligram once-a-day, given what you have seen in the other trials?
Carl Pelzel
Cost and timing. And frankly, we feel really good about the 1200-milligram dose.
Scott Henry – Roth Capital
Okay. Fair enough. I look forward to seeing those abstracts as well. Just on a housekeeping question, the royalties in the quarter, 433,000 was a pretty strong number. Should we expect that to continue forward?
Tammy Cameron
Yes. That was driven primarily by the IVAX settlement. So there is royalty coming through just above 300,000 this quarter related to that settlement.
Scott Henry – Roth Capital
Okay. And those should continue on?
Carl Pelzel
They will continue on until we hit the $2.5 million cap. It will vary slightly because it's an effective 9% royalty on the sales of Teva's and IVAX's Glucophage XR. So, it's pretty stable at the moment, but you might see it go up or down over time.
Scott Henry – Roth Capital
Great. Thank you for taking the questions.
Carl Pelzel
Thank you, Scott.
That does conclude our question-and-answer session. At this time, I'll turn the call back over to Carl for any concluding or additional remarks.
Carl Pelzel
Thank you very much for joining us on this call, and I look forward to keeping you apprised of our progress in the coming months. Good afternoon.
This does conclude our conference call for today. We thank everyone for your participation.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!


text:
track list
Album Brain Damage Tour of Europe
Released January 01, 1983
This site contains content from artists, fans, and writers from around the internet in it's natural form. Such content is not representative of Viacom Media Networks.
©2017 Viacom International Inc. All Rights Reserved. MTV and all related titles and logos are trademarks of Viacom International Inc.


text:
We offer discount to nonprofits, government agencies, and federal contractors
AILA makes recommendations to restore due process for Central American children, families, and adults seeking asylum and legal protection at our border. Read Report Today
AILA Doc. No. 14071654 | Dated July 16, 2014
On 7/16/14 Sen. Cornyn (R-TX) and Rep. Cuellar (D-TX) introduced the "Helping Unaccompanied Minors and Alleviating National Emergency (HUMANE) Act.
Cite as AILA Doc. No. 14071654.
American Immigration Lawyers Association
1331 G Street NW, Suite 300
Washington, DC 20005
Copyright © 1993-2017
American Immigration Lawyers Association.